AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials
Daniela Berg(Christian-Albrechts-Universität zu Kiel), Baltazar Gomez‐Mancilla(Novartis (Switzerland)), Christine Schneider(KLA (United States)), IIona Csoti(KLA (United States)), Claudia Trenkwalder(Paracelsus Elena Klinik Kassel), Marc Vandemeulebroecke(Novartis (Switzerland)), Martin Wolz(KLA (United States)), F. Gasparini(Novartis (Switzerland)), Alexander Storch(German Center for Neurodegenerative Diseases), Jana Godau(Hertie Institute for Clinical Brain Research), Sam Hariry(Novartis (Switzerland)), María Stamelou(National and Kapodistrian University of Athens), Karla Eggert(Philipps University of Marburg), Katy Cooke, Vincent Ries(Philipps University of Marburg), Thérèse Di Paolo(Université Laval), Walid Abi‐Saab(Novartis (Switzerland)), Heiko Huber(German Center for Neurodegenerative Diseases), Donald R. Johns(Novartis (Switzerland)), M. Morelli‐Canelo(Paracelsus Elena Klinik Kassel)
Cited by 173
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
MDS research criteria for prodromal Parkinson's disease
|Movement Disorders|2015|1.3k